Last reviewed · How we verify

Insulin treatment during Ramadan

Meir Medical Center · FDA-approved active Small molecule Quality 5/100

Insulin treatment during Ramadan is a Small molecule drug developed by Meir Medical Center. It is currently FDA-approved.

Insulin treatment during Ramadan, marketed by Meir Medical Center, is a specialized therapy designed for patients observing the fasting month. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk is the lack of robust clinical trial data to support its efficacy and safety, which could limit its market acceptance.

At a glance

Generic nameInsulin treatment during Ramadan
SponsorMeir Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Insulin treatment during Ramadan

What is Insulin treatment during Ramadan?

Insulin treatment during Ramadan is a Small molecule drug developed by Meir Medical Center.

Who makes Insulin treatment during Ramadan?

Insulin treatment during Ramadan is developed and marketed by Meir Medical Center (see full Meir Medical Center pipeline at /company/meir-medical-center).

What development phase is Insulin treatment during Ramadan in?

Insulin treatment during Ramadan is FDA-approved (marketed).

Related